Literature DB >> 17397920

Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia.

Giulia Cervetti, Giovanni Carulli, Sara Galimberti, Antonio Azzarà, Elisa Cannizzo, Gabriele Buda, Enrico Orciuolo, Mario Petrini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17397920     DOI： 10.1016/j.leukres.2007.02.013

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  3 in total

1.  Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia.

Authors:  Shin Nakayama; Tokiko Nagamura-Inoue; Kazuaki Yokoyama; Nobuhiro Ohno; Jun Ooi; Satoshi Takahashi; Kaoru Uchimaru; Toru Iseki; Arinobu Tojo
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

Review 2.  Immunological off-target effects of imatinib.

Authors:  Laurence Zitvogel; Sylvie Rusakiewicz; Bertrand Routy; Maha Ayyoub; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2016-03-31       Impact factor: 66.675

3.  Chronic myeloid leukaemia and human immunodeficiency virus (HIV) infection.

Authors:  Michael J Webb; Claire L Barrett; Christel Pretorius; Magdalena F van Jaarsveld; Vernon J Louw
Journal:  Int J Hematol       Date:  2012-04-20       Impact factor: 2.319
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.